Abstract
HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antibodies, Viral / blood
-
Antineoplastic Agents / blood
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / blood
-
HIV Protease Inhibitors / blood
-
HIV Protease Inhibitors / therapeutic use*
-
HIV Seronegativity
-
Herpesvirus 8, Human / immunology
-
Humans
-
Indinavir / blood
-
Indinavir / therapeutic use*
-
Middle Aged
-
Sarcoma, Kaposi / blood
-
Sarcoma, Kaposi / drug therapy*
-
Treatment Outcome
Substances
-
Antibodies, Viral
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
HIV Protease Inhibitors
-
Indinavir